Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database

Post time 5 day(s) ago

journal：Japanese Journal of Clinical Oncology

Authors：Yoichiro Tohi; Yuri Kitadani; Takuma Kato; Shunsuke Nakamura; Naoya Kani; Iori Matsuda; Kana Kohashiguchi; Yohei Abe; Hirohito Naito; Homare Okazoe; Rikiya Taoka; Fumiaki Mikami; Mikio Sugimoto

Published date：--

DOI：10.1093/jjco/hyag145

PDF link：https://academic.oup.com/jjco/ad ... 0831751/hyag145.pdf

Article link：https://doi.org/10.1093/jjco/hyag145

Article Source：Oxford University Press (OUP)。

Remark：

Post time 5 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Oxford] Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Oxford] Darolutamide-based triplet therapy versus androgen receptor pathway inhibitor-based doublet therapy for metastatic castration-sensitive prostate cancer: a real-world analysis using the TriNetX database Copy